These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22754405)

  • 1. The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.
    Koola MM; Wehring HJ; Kelly DL
    J Dual Diagn; 2012; 8(1):50-61. PubMed ID: 22754405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of people on long-acting injectable antipsychotics in Australia: Data from the 2010 National Survey of High Impact Psychosis.
    Suetani S; Siskind D; Phillipou A; Waterreus A; Morgan VA; Castle D
    Aust N Z J Psychiatry; 2021 Oct; 55(10):958-975. PubMed ID: 33906481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome.
    Olagunju AT; Clark SR; Baune BT
    Aust N Z J Psychiatry; 2019 Jun; 53(6):509-527. PubMed ID: 30957510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review.
    Coles AS; Knezevic D; George TP; Correll CU; Kane JM; Castle D
    Front Psychiatry; 2021; 12():808002. PubMed ID: 34975600
    [No Abstract]   [Full Text] [Related]  

  • 8. Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia.
    Correll CU; Lauriello J
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32609958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
    Højlund M; Kemp AF; Haddad PM; Neill JC; Correll CU
    Lancet Psychiatry; 2021 Jun; 8(6):471-486. PubMed ID: 34023019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study.
    Lynn Starr H; Bermak J; Mao L; Rodriguez S; Alphs L
    Schizophr Res; 2018 Apr; 194():39-46. PubMed ID: 28601497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
    Kishimoto T; Robenzadeh A; Leucht C; Leucht S; Watanabe K; Mimura M; Borenstein M; Kane JM; Correll CU
    Schizophr Bull; 2014 Jan; 40(1):192-213. PubMed ID: 23256986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.
    Masand PS; Gupta S
    Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
    Achilla E; McCrone P
    Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
    Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
    Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
    Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
    J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials.
    Kishi T; Oya K; Iwata N
    Int J Neuropsychopharmacol; 2016 Sep; 19(9):. PubMed ID: 27207910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).
    Brugnoli R; Rapinesi C; Kotzalidis GD; Marcellusi A; Mennini FS; De Filippis S; Carrus D; Ballerini A; Francomano A; Ducci G; Del Casale A; Girardi P
    Riv Psichiatr; 2016; 51(2):47-59. PubMed ID: 27183509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
    Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
    J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.